Boehringer Ingelheim increases access to the medication for the treatment of HIV/AIDS

Boehringer IngelheimBoehringer Ingelheim is announcing an expansion of its Intellectual Property (IP) enforcement policy. The IP enforcement policy had already been amended in 2007 by an easy-to-use, non-assert declaration for Viramune® (nevirapine). At present, twelve WHO pre-qualified manufacturers qualify for the non-assert declaration for Viramune® and Boehringer Ingelheim grants tiered pricing to 78 countries.

Under the revised IP enforcement policy, Boehringer Ingelheim will not enforce its nevirapine patent rights, provided generic versions of Viramune® are of acceptable quality and for use in eligible countries. Today's expanded IP enforcement policy will further increase access to HIV/Aids medication in emerging economies.

The decision to waive enforcement of its patent rights for nevirapine use in a total of 135 low- and middle-income countries is the result of a close cooperation between Boehringer Ingelheim and the Medicines Patent Pool (MPP). The United Nations-backed public health organisation MPP works to improve access to HIV, Hepatitis C and tuberculosis medicines in low- and middle-income countries.

"The core task of Boehringer Ingelheim is the research and development of innovative medication. We feel responsible for making innovative medicines like nevirapine accessible and affordable for patients in developing countries," explains Yew Looi Liew, Senior Vice President Emerging Markets at Boehringer Ingelheim. "Through making these medicines available we address an unmet medical need and can save lives - especially in low-income societies."

The research-driven company Boehringer Ingelheim has a significant history in the commitment of improving access to its anti-retroviral medication. The Viramune® Donation Programme was initiated in 2000 in order to facilitating access of anti-retroviral drugs for pregnant women with HIV/Aids. From its inception, the initiative reached more than two million mother-child-pairs in 164 programmes in 60 countries worldwide.

The Medicines Patent Pool (MPP) seeks to increase access to medicines by negotiating with pharmaceutical companies for voluntary licenses on their medicines patents. The work of the MPP has been endorsed by the World Health Organization, UNAIDS, The Global Fund to Fight Aids, Tuberculosis and Malaria, and the Group of Eight (G8) Industrialised Nations (France, Germany, Italy, United Kingdom, Japan, United States, Canada and Russia). The MPP was founded and continues to be funded by the innovative financing mechanism UNITAID.

About Boehringer Ingelheim
Boehringer Ingelheim is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally through 145 affiliates and a total of some 47,500 employees. The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects through, for example, the initiative "Making More Health" while also caring for employees. Respect, equal opportunity and reconciling career and family form the foundation of mutual cooperation. The company also focuses on environmental protection and sustainability in everything it does.

In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 per cent ofnet sales.

Most Popular Now

FDA approves drug to treat ALS

The U.S. Food and Drug Administration today approved Radicava (edaravone) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig's...

Read more

FDA approves first cancer treatment for any solid …

The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker). This is th...

Read more

Sanofi and Regeneron announce FDA Approval of Kevz…

Sanofi and Regeneron Pharmaceuticals, Inc. have announced the U.S. Food and Drug Administration (FDA) approval of Kevzara® (sarilumab) for the treatment of adult patients...

Read more

AstraZeneca marks a key milestone with the ‘toppin…

AstraZeneca marks a key milestone in its successful move to Cambridge, UK, with the 'topping out' of its new, state-of-the-art, strategic R&D centre and global corporate ...

Read more

FDA approves first treatment for a form of Batten …

The U.S. Food and Drug Administration today approved Brineura (cerliponase alfa) as a treatment for a specific form of Batten disease. Brineura is the first FDA-approved ...

Read more

Abbott announces CE Mark and first use of the worl…

Abbott (NYSE: ABT) today announced CE Mark and first use of the new Confirm RxTM Insertable Cardiac Monitor (ICM), the world's first smartphone compatible ICM that will h...

Read more

Imfinzi significantly reduces the risk of disease …

AstraZeneca and MedImmune, its global biologics research and development arm, today announced positive results for the Phase III PACIFIC trial, a randomised, double-blind...

Read more

Antibiotic doxycycline may offer hope for treatmen…

A study published in the journal Scientific Reports suggests that doxycycline, an antibiotic used for over half a century against bacterial infections, can be prescribed ...

Read more

Novartis exercises exclusive option agreement with…

Novartis announced today that it has notified Conatus Pharmaceuticals Inc., of its exercise of the option to an exclusive license for the global development and commercia...

Read more

England's Cancer Drugs Fund 'failed to deliver mea…

Analysis of the drugs that were approved for use by the NHS Cancer Drugs Fund (CDF) in England has shown that the fund was not good value for patients and society and may...

Read more

High levels of exercise linked to nine years of le…

Despite their best efforts, no scientist has ever come close to stopping humans from aging. Even anti-aging creams can't stop Old Father Time. But new research from Brigh...

Read more

Vitamin A deficiency is detrimental to blood stem …

Many specialized cells, such as in the skin, gut or blood, have a lifespan of only a few days. Therefore, steady replenishment of these cells is indispensable. They arise...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]